About OMIXON, INC
Omixon is a molecular diagnostics company focused on transitioning the HLA community to Next Generation Sequencing (NGS) technologies, offering products such as NanoTYPE HLA-11 Plus and Holotype HLA. The company was acquired by Werfen in 2024.
Next Generation Sequencing (NGS) for HLA genotypingDevelopment of NGS-based HLA genotyping assays and softwareNanoTYPE™ nanopore-based long-read sequencing technologySingle locus testing with NANOTYPE MONO™ and MONOall™HLA Twin™ genotyping software for automated analysisTraining and support for HLA labs worldwide
Recent Federal Awards
| Award | Agency | Amount | Date |
|---|---|---|---|
| Federal contract award | Department of Health and Human Services | $20K | |
| Federal contract award | Department of Health and Human Services | $169K | |
| Federal contract award | Department of Health and Human Services | $20K | |
| Federal contract award | Department of Health and Human Services | $20K |
Is this your company?
Claim this profile to keep it accurate — and see the federal & state opportunities GovIntel's AI has matched to OMIXON, INC right now.
Claim this profile See matched opportunitiesData compiled from public government sources including SAM.gov, USAspending.gov, and state procurement records. Last verified against federal award records. Inaccurate? Let us know.